Research Keyword: psilocybin

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds

mycolabadmin

Scientists extracted and analyzed psilocybin and psilocin from Psilocybe cubensis mushrooms to develop a medication for treating mental health disorders like depression and anxiety. Using various analytical techniques, they confirmed the extract contained about 3.26% psilocybin and was safe, pure, and stable. The research shows that creating a psilocybin-based medicine from these mushrooms is feasible and could offer a new treatment option for people struggling with mental health issues.

Read More »

Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms

mycolabadmin

This study reveals that two different types of magic mushrooms—Psilocybe and Inocybe—make psilocybin (the active compound in magic mushrooms) using completely different enzymes and chemical pathways. Despite both mushroom types producing the same final product, they evolved their recipes independently, like two chefs arriving at the same dish through entirely different cooking methods. The research shows how evolution can solve the same problem in multiple ways and provides new enzymes that could be useful for producing psilocybin as a potential depression treatment.

Read More »

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

Scientists studied magic mushrooms at different growth stages to understand their chemical makeup. They found that mature mushroom caps contain high levels of psilocybin (the psychedelic compound) but the root-like mycelium contains different beneficial compounds like ergothioneine and choline. This suggests mycelium could be developed as a therapeutic product without the psychedelic effects, potentially offering health benefits while avoiding the mind-altering properties.

Read More »

Adaptation and latent structure of the Brazilian version of the Ego Dissolution Inventory (EDI-BR): an exploratory study

mycolabadmin

This study adapted a psychological assessment tool called the Ego Dissolution Inventory for use in Brazil. Ego dissolution refers to the profound sense of losing one’s sense of self that people experience when using psychedelics like psilocybin mushrooms and LSD. The researchers found that the adapted Brazilian version works well and identifies three dimensions of the experience: confidence/assertiveness, ego dissolution, and ego inflation. This validated tool can now help researchers in Brazil better understand psychedelic experiences and their potential therapeutic benefits.

Read More »

Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis

mycolabadmin

This comprehensive review examined how psilocybin affects thinking and attention. Researchers analyzed 13 studies and found that psilocybin slows down reaction times during tasks requiring focus and decision-making, though accuracy remains relatively stable. The effects increase with higher doses. Understanding these cognitive changes is important for both therapeutic applications and ensuring safe use of psilocybin in research and clinical settings.

Read More »

Determination of Tryptamine Alkaloids and Their Stability in Psychotropic Mushrooms

mycolabadmin

Researchers analyzed the active compounds found in psychotropic mushrooms used for therapy and microdosing. They found that the amounts of these compounds vary greatly between mushroom samples and can degrade during storage. Fresh mushrooms stored in freezers degraded faster than dried mushrooms kept at room temperature in the dark, suggesting proper storage is important for maintaining therapeutic effectiveness.

Read More »
Scroll to Top